Program Goals

The purpose of this CME activity is to educate practicing physicians and other healthcare professionals about the recent developments in our understanding of the mechanisms of action of ketogenic metabolic therapy (KMT) in psychiatry. To advance the field, it is crucial to have a mechanistic understanding of KMT that is linked to pathophysiological processes underlying Severe Mental Illness (SMI). This activity will review the molecular and mechanistic published data that demonstrates KMT acts though diverse but interlinked common disease pathways to directly target underlying pathophysiology.

Target Audience

This activity is designed for primary care and psychiatric physicians, nurse practitioners and physician assistants as well as licensed mental health therapists and dieticians.  All levels of experience are welcome.

Learning Objectives

After completing the activity, the participant should be better able to:

1. Explain the systemic and brain metabolic and bioenergetic abnormalities in SMI.
2. Describe the potential contribution of circulating ketones and the gut microbiome in the mediation of the effects of KTM.
3. Recognize the effects of KMT on bioenergetics, mitochondrial functions, and oxidative stress.
4. Explain how KMT might reduce systemic and brain inflammatory process.
5. Identify the effects of KMT to target excitation/inhibition imbalance in the brain through acting on key neurotransmitters and ion channels.
6. Organize acquired knowledge on the latest findings on the Mechanisms of Ketogenic Therapy in Metabolic Psychiatry into current practice to better address the needs of their patients, to educate patients, and to optimize patient outcomes.

	Zoltan Sarnyai, MD, PhD Director, Margaret Roderick Centre for Mental Health Research Professor and Head, Laboratory of Psychiatric Neuroscience James Cook University, Australia
	Julie Milder, PhD Director, Neuroscience Baszucki Group Unites States

European Accreditation Council for Continuing Medical Education (EACCME)
EACCME Accreditation Statement
The Metabolic Consequences of Psychiatric Medications and Options for Management, made available on https://www.medtalks.com/therapy-metabolic-psychiatry and organized by Dane Garvin Ltd., is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists.
 
Only those e-learning materials that are displayed on the UEMS-EACCME® website have formally been accredited.
 
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.
 
EACCME Term Offering
January 23, 2026 to January 23, 2028
 
Information regarding the conversion of EACCME® credits
Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at https://edhub.ama-assn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA. 
 
For other countries, please contact the relevant national/regional accreditation authority.
 
American Association of Nurse Practitioners (AANP) Accreditation
AANP Accreditation Statement
This activity is approved for 2.25 contact hour(s) of continuing education (which includes 0.0 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 25127602. This activity was planned in accordance with AANP Accreditation Standards and Policies. This activity was released on December 31, 2025 and is valid for American Association of Nurse Practitioners credit for two years. Requests for credit must be made no later than December 31, 2027.